The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children

University Hospital, Strasbourg, France

Status: Enrolling

Conditions: Epilepsy in Children

Study type: Observational

Funder types: Other

Identifiers

NCT06498362

9067

Details and patient eligibility

About

Status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). It is defined as the occurrence of a crisis lasting more than 5 minutes and requiring the implementation of treatment to stop it and thus limit the immediate and long-term consequences.

The research hypothesis is that LEVETIRACETAM is non-inferior to PHENYTOIN in terms of cessation and absence of recurrence of status epilepticus, with better clinical tolerance in children from 3 months to 17 years old, with or without epileptic disease, with or without a history of status epilepticus

Enrollment: 151 estimated patients

Sex: All

Ages: 3 months to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Minor patient aged 3 months to 17 years
• 2nd line treatment with LEVETIRACETAM or PHENYTOIN after failure of benzodiazepines
• Supported in one of the participating centers during the period from November 1, 2019 to May 31, 2023
• Subject or parents who have not expressed, after information, their opposition to the reuse of their data for the purposes of this research.

Exclusion criteria

• Patient or parents having expressed their opposition to participating in the study.